4//SEC Filing
KREHER NERISSA 4
Accession 0001689375-23-000062
CIK 0001689375other
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 5:08 PM ET
Size
12.6 KB
Accession
0001689375-23-000062
Insider Transaction Report
Form 4
KREHER NERISSA
Chief Medical Officer
Transactions
- Award
Common Stock
2023-09-01+14,200→ 41,330 total - Sale
Common Stock
2023-09-06$13.46/sh−871$11,728→ 40,058 total - Tax Payment
Common Stock
2023-09-05$14.46/sh−401$5,799→ 40,929 total - Sale
Common Stock
2023-09-06$14.00/sh−21$294→ 40,037 total - Award
Stock Option (Right to Buy)
2023-09-01+21,500→ 21,500 totalExercise: $15.41Exp: 2033-09-01→ Common Stock (21,500 underlying)
Footnotes (5)
- [F1]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- [F2]This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
- [F3]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.
Documents
Issuer
Entrada Therapeutics, Inc.
CIK 0001689375
Entity typeother
Related Parties
1- filerCIK 0001741850
Filing Metadata
- Form type
- 4
- Filed
- Sep 5, 8:00 PM ET
- Accepted
- Sep 6, 5:08 PM ET
- Size
- 12.6 KB